TSD Life Science
- Biotech or pharma, therapeutic R&D
TSD Life Science is a biotech company founded in 2016. Leveraging two differentiated platform technologies, we are developing next-generation immuno-oncology solutions. Our pipeline includes an iPSC-derived NK cell therapy engineered to express IL-7 and CCL19, and a small molecule kinase inhibitor targeting metastatic castration resistant prostate cancer(mCRPC) based on a proprietary scaffold. With strong R&D capabilities, we are committed to transforming the future of cancer treatment.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}